Get started
Work

LBA47 A phase II study evaluating tipifarnib in mHRAS, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (AIM-HN study)

Year: 2023
Type: article
DOI: 10.1016/j.annonc.2023.10.041
Authors: A.L. Ho, D.R. Adkins, G.J. Hanna, J. Bruce, M-J. Ahn, L. Iglesias Docampo, H. Kang, D.J. Wong, A. Psyrri, M. Gillison, I. Braña, Y.C. Liu, C-Y. Hsieh, M.H. Hong, Z. Zhang, B. Balsara, A. Saunders, A. Gasco Hernandez, S. Dale, R. Haddad
Institutions: Memorial Sloan Kettering Cancer Center, Washington University in St. Louis, Dana-Farber Cancer Institute, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Samsung Medical Center, Sungkyunkwan University, Hospital Universitario 12 De Octubre, University of California, San Francisco, University of California, Los Angeles, University General Hospital Attikon, The University of Texas MD Anderson Cancer Center, Vall d'Hebron Hospital Universitari, Taichung Veterans General Hospital, China Medical University, China Medical University Hospital, Yonsei University, Severance Hospital, Yonsei University Health System, Kura Oncology (United States)
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W4387809657
FWCI: 1.755
Cites:
Cited by: 8
Related to: 10